NeuroPace, Inc. (NPCE)
| Market Cap | 437.98M +21.2% |
| Revenue (ttm) | 106.99M +33.2% |
| Net Income | -19.11M |
| EPS | -0.57 |
| Shares Out | 34.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,169 |
| Open | 12.58 |
| Previous Close | 12.67 |
| Day's Range | 12.51 - 13.06 |
| 52-Week Range | 9.22 - 19.60 |
| Beta | 1.87 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+56.74%) |
| Est. Earnings | Nov 3, 2026 |
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programmin... [Read more]
Financial Performance
In 2025, NeuroPace's revenue was $99.99 million, an increase of 25.13% compared to the previous year's $79.91 million. Losses were -$21.47 million, -20.91% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for NPCE stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 56.74% from the latest price.
News
NeuroPace initiated with an Overweight at KeyBanc
KeyBanc analyst Brett Fishbin last night initiated coverage of NeuroPace (NPCE) with an Overweight rating and $18 price target The company is “effectively commercializing a differentiated approach” to...
NeuroPace initiated with an Overweight at KeyBanc
KeyBanc initiated coverage of NeuroPace (NPCE) with an Overweight rating and $18 price target
NeuroPace Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Strong core growth continues with a 21% revenue increase and robust patient pipeline. FDA approval for IGE could expand the addressable market by 20%, with compelling clinical data supporting broad adoption. AI-driven tools and remote monitoring aim to reduce friction and support scalable growth.
NeuroPace Transcript: Wells Fargo 21st Annual Healthcare Conference
Drug-resistant epilepsy remains under-penetrated, with new initiatives and expanded indications like IGE expected to drive adoption. The RNS system's clinical data and AI tools position it for growth, with FDA approval for IGE potentially in 2027 and a ramp-up in commercialization to follow.
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace Earnings Call Transcript: Q2 2026
Q2 revenue grew 17% to $22.8M, with RNS System revenue up 21% year-over-year and record highs in prescribers and patient pipeline. Guidance for 2026 was raised, reflecting strong core business momentum, while the IGE regulatory process continues with optimism for approval.
NeuroPace Earnings release: Q2 2026
NeuroPace released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
NeuroPace Quarterly report: Q2 2026
NeuroPace has published its Q2 2026 quarterly earnings report on August 11, 2026.
NeuroPace Slides: Q2 2026
NeuroPace has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
NeuroPace reports Q2 EPS (18c), consensus (20c)
Reports Q2 revenue $22.83M, consensus $22.65M. Second-quarter performance showed continued momentum in our core RNS business driven by increased adoption within our current focal epilepsy indication,”...
NeuroPace raises FY26 revenue view to $99.5M-$101.5M from $99M-$101M
Consensus is $99.91M. Other FY26 guidance: Increase full year non-GAAP gross margin to between 82.0% and 83.0%, an increase compared to 81.5% to 82.5% previously; Reiterate full year non-GAAP operatin...
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...
NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial
NeuroPace (NPCE) on Tuesday provided an update on the U.S. Food and Drug Administration review of the company’s Premarket Approval Panel Track Supplement seeking to expand the labeled indication for…
NeuroPace Transcript: FDA announcement
FDA found the PMA supplement for RNS System expansion to drug-resistant IGE not approvable as submitted, requesting more clinical data but willing to collaborate. NAUTILUS trial data show strong safety/efficacy. The company will submit more info via SIR; no new trials required. Review timelines may not reset; financial guidance unchanged.
NeuroPace Press release: FDA announcement
NeuroPace issued a press release on July 28, 2026, disclosing material business information to investors.
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. ...
NeuroPace initiated with an Outperform at Mizuho
Mizuho initiated coverage of NeuroPace (NPCE) with an Outperform rating and $22 price target The firm’s neurology survey indicates “significant upside potential” for the company’s responsive neurostim...
NeuroPace Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and governance procedures. Both proposals passed with strong support, and no questions were raised by shareholders. Forward-looking statements and risk factors were acknowledged.
NeuroPace announces FDA approval of ECoG Assistant
NeuroPace (NPCE) announced FDA approval of ECoG Assistant. This milestone represents an important step in NeuroPace’s broader AI platform strategy. “This approval underscores how NeuroPace’s data adva...
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will...
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG ...
NeuroPace price target raised to $20 from $19 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on NeuroPace (NPCE) to $20 from $19 and keeps a Buy rating on the shares following quarterly results. According to management, the company…
NeuroPace reports Q1 EPS (20c), consensus (23c)
Reports Q1 revenue $22.1M, consensus $21.7M. “First quarter results reflect continued execution against the strategic priorities we outlined earlier this year,” said Joel Becker, Chief Executive Offic...
NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
Consensus $98.9M. Reiterates FY26 gross margin between 81.5% and 82.5% and increases Adjusted EBITDA to ($8.5M) and ($9.5M) compared to previous guidance between ($9.0M) to ($10.0M).